Tirzepatide has an obviously lower affinity with GIPR than GIP does (pIC 50 : 6.70 vs 7.87), and its cAMP activity is approximately equal to that of GIP
(Link) Medcase adopts Awells CareOps Platform for faster care flow design
Historical or previous use of sMRA was observed in 10.914.0% of patients, and recent use was recorded for 9.5% of patients
October 2023 : A study of 16 million patients (2006-2020) found that those who used GLP-1 agonists for weight loss were at a higher risk of pancreatitis, bowel obstruction, and gastroparesis compared to those who took bupropion-naltrexone instead
EPA and DHA also can modulate GLP-1 levels and improve post-meal glucose control by helping the body respond in a healthy manner to inflammation in the gut
Wegovy Tablets: Initial dose (days 1 through 30): 1.5 mg orally once a day Dose escalation: Days 31 through 60: 4 mg orally once a day Days 61 through 90: 9 mg orally once a day SUBCUTANEOUS: Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose for glycemic control: 0.5 to 2 mg subcutaneously once a week, based on glycemic control If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dose: Increase to 1 mg subcutaneously once a week